Medindia
Advertisement

Neuron Excitability in ALS Could be Reduced by a New Drug

by Ramya Rachamanti on December 11, 2018 at 11:14 AM

Neuron Excitability in ALS Could be Reduced by a New Drug
Results of a new phase 2 clinical trial on ezogabine (or retigabine) were presented by Brian Wainger, MD, PhD, of the Healey Center for ALS at Massachusetts General Hospital (MGH) at the Motor Neurone Disease Association annual meeting in Glasgow.

The trial met its main goal of measuring a reduction in motor neuron excitability in people with amyotrophic lateral sclerosis (ALS) following treatment with ezogabine.
Advertisement


ALS - also called Lou Gehrig's disease or motor neuron disease - is a progressive neurodegenerative disorder that leads to the death of neurons in the brain and spinal cord.

There are only three drugs with limited effects approved in the United States for treating ALS, and new therapies that substantially prolong lifespan are urgently needed.
Advertisement

An essential step toward developing new treatment avenues is unraveling the biological processes that go awry in this disorder and identifying novel molecular targets for drug intervention.

Ezogabine has a unique mechanism of action of activating the Kv7 or KCNQ family of voltage-gated potassium channels in cell membranes and can calm the excitability of nerve cells that cause seizures.

Similar "hyperexcitability" in motor neurons may play a role in ALS, and the study - conducted by investigators from the MGH Neurological Clinical Research Institute (NCRI) at sites of the Northeast ALS Consortium - evaluated ezogabine's potential in the context of ALS.

The investigators used transcranial magnetic stimulation and threshold tracking nerve conduction studies to measure the effects of ezogabine on upper and lower motor neuron excitability in 65 people with ALS and found that treatment did reduce motor neuron excitability. The study was not powered to assess clinical outcomes.

This trial was supported by The ALS Association, GlaxoSmithKline, the Harvard Stem Cell Institute (HSCI) and the MGH NCRI.

Preclinical studies in human induced pluripotent stem cells (iPSCs) leading up to the clinical trial, performed at Boston Children's Hospital and Harvard University, were supported by The ALS Association, HSCI, the National Institute of Neurological Disorders and Stroke, the New York Stem Cell Foundation and Target ALS.

Wainger is a New York Stem Cell Foundation - Robertson Investigator

"This novel study provides us with a better understanding of neuron hyperexcitability, an important ALS disease pathway, and we are thrilled to be a part of such a powerful collaborative team," says Calaneet Balas, president and CEO of The ALS Association.

Lucie Bruijn, PhD, MBA, chief scientist, The ALS Association, adds, "This is the first clinical trial for ALS that was designed using data based on an iPSC model of ALS and was possible in part due to the availability of a biomarker in people living with disease that measures excitability of motor neurons, also characterized in the iPSC model."



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
'Hybrid Immunity' may Help Elude COVID-19 Pandemic
Stroop Effect
Plant-Based Diet may Reduce the Risk of COVID-19
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Parkinsons Disease Parkinsons Disease Surgical Treatment Clinical Trials - Different Phases of the trial Signature Drug Toxicity Amyotrophic Lateral Sclerosis (ALS) Drugs Banned in India Acute Coronary Syndrome 

Recommended Reading
What is the Connection Between Exercise and Amyotrophic Lateral Sclerosis?
Intense physical activity and Amyotrophic Lateral Sclerosis (ALS) are not so unrelated subjects ......
Acute Coronary Syndrome
Acute coronary syndrome (ACS) is a sudden, acute life-threatening condition caused by a dramatic red...
Amyotrophic Lateral Sclerosis (ALS)
Find out more about the degenerative disease- Amyotrophic lateral sclerosis....
Clinical Trials - Different Phases of the trial
Clinical trials serve as a vital component for improving the treatment of medical conditions as they...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Drugs Banned in India
Several drugs are either banned or withdrawn after introduction in the market....
Parkinsons Disease
Parkinson’s disease is a neurodegenerative disease caused by progressive dopamine brain cells loss. ...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use